BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Tidwell J, Balassiano N, Shaikh A, Nassar M. Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review. World J Hepatol 2023; 15(8): 1001-1012 [PMID: 37701920 DOI: 10.4254/wjh.v15.i8.1001]
URL: https://www.wjgnet.com/1948-5182/full/v15/i8/1001.htm
Number Citing Articles
1
Rahnuma Ahmad, Mainul Haque. Metformin: Beyond Type 2 Diabetes MellitusCureus 2024;  doi: 10.7759/cureus.71730
2
Naim Alkhouri, Michael Charlton, Meagan Gray, Mazen Noureddin. The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologistsExpert Opinion on Investigational Drugs 2025; 34(3): 169 doi: 10.1080/13543784.2025.2473062
3
Hazem Abosheaishaa, Mahmoud Nassar, Omar Abdelhalim, Ammar Ayman Bahbah, Sharif Abbas, Samah M. Morsi, Muhammad Ghallab, Zakaria Alagha, Ahmed Omran, Khaled Elfert, Praneeth Bandaru, Arnold Nongmoh Forlemu, Madhavi Reddy. Relation between non-alcoholic fatty liver disease and carotid artery intimal media thickness as a surrogate for atherosclerosis: a systematic review and meta-analysisEuropean Journal of Gastroenterology & Hepatology 2024; 36(5): 592 doi: 10.1097/MEG.0000000000002721
4
Cristina Elena Negroiu, Robertina Iulia Tudoraşcu , Maria Cristina Beznă , Adrian Ionuţ Ungureanu , Sorina Octavia Honţaru , Suzana Dănoiu . The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative reviewRomanian Journal of Morphology and Embryology 2024; 65(2): 159 doi: 10.47162/RJME.65.2.02
5
Hazem Abosheaishaa, Mai Hussein, Muhammad Ghallab, Magdy Abdelhamid, Natalie Balassiano, Md Ripon Ahammed, Muhammad Almas Baig, Jawad Khan, Moaz Elshair, Moataz Yousry Soliman, Mohammed Abdelwahed, Amr Ali, Ahmed Alzamzamy, Mahmoud Nassar. Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: A systematic review and meta-analysisDiabetes & Metabolic Syndrome: Clinical Research & Reviews 2024; 18(1): 102938 doi: 10.1016/j.dsx.2023.102938
6
Asumi Yamazaki, Yuka Takachi, Hirokazu Takahashi, Nagisa Hara, Yuji Ogawa, Hideyuki Hyogo, Masahiro Koseki, Mariko Hayakawa, Atsushi Nakajima, Michihiro Iwaki, Makoto Fujii, Takayuki Ishida, Yoshihiro Kamada. Quantitative color analysis of the diets of patients with metabolic dysfunction‐associated steatotic liver disease: Comparative study with nutritionally balanced dietsHepatology Research 2025; 55(3): 398 doi: 10.1111/hepr.14138
7
Fabrizio AMATO, Martina MARANO, Kamela GJINI, Lorenza VAIRA, Elisabetta BUGIANESI, Angelo ARMANDI. Novel dynamic and static biomarkers for the assessment of liver disease severity in MASLDMinerva Biotechnology and Biomolecular Research 2024; 36(4) doi: 10.23736/S2724-542X.24.03186-9
8
Benjamin Wildman-Tobriner. Photon-counting Detector CT: A Promising Tool for Noninvasive Liver Fat AssessmentRadiology 2024; 312(3) doi: 10.1148/radiol.241963
9
Emilio Merlo Pich, Ioannis Tarnanas, Patrizia Brigidi, Ginetta Collo. Gut Microbiome-Liver-Brain axis in Alcohol Use Disorder. The role of gut dysbiosis and stress in alcohol-related cognitive impairment progression: possible therapeutic approachesNeurobiology of Stress 2025; 35: 100713 doi: 10.1016/j.ynstr.2025.100713
10
Georgiana-Diana Cazac-Panaite, Cristina-Mihaela Lăcătușu, Elena-Daniela Grigorescu, Adina-Bianca Foșălău, Alina Onofriescu, Bogdan-Mircea Mihai. Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and CirrhosisJournal of Clinical Medicine 2025; 14(4): 1042 doi: 10.3390/jcm14041042
11
Hazem Abosheaishaa, Omar Nassar, Mostafa Alfishawy, Anthony Martinez . Prevalence of Metabolic-Associated Steatotic Liver Disease in Patients with Type 2 Diabetes with and without HIV: Retrospective Multicenter StudyASIDE Internal Medicine 2025; 1(2): 8 doi: 10.71079/ASIDE.IM.02202518
12
Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic. MAFLD Pandemic: Updates in Pharmacotherapeutic Approach DevelopmentCurrent Issues in Molecular Biology 2024; 46(7): 6300 doi: 10.3390/cimb46070376
13
Kannan Sridharan, Gowri Sivaramakrishnan. Therapeutic Potential of Sodium–Glucose Cotransporter-2 Inhibitors in Nonalcoholic Fatty Liver Disease: A Network Meta-analysisAmerican Journal of Therapeutics 2025; 32(3): e297 doi: 10.1097/MJT.0000000000001813